Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals, Inc. Q2 FY26 Results — Earnings Call Analysis
Q2 FY26 earnings call: what management guided on revenue, margins and order book.
What the Q2 FY26 call signalled
3 of 4 strong
The short version
- REDEMPLO launch momentum continues strong with prescriptions accelerating nearly threefold over the quarter and surpassing 400 total prescriptions since launch. - No specific future guidance on earnings, operating earnings, profits, or EPS was provided during the call.
From Arrowhead Pharmaceuticals, Inc.'s Q2 FY26 earnings-call transcript · updated 30 May 2026.
Revenue & Sales Performance
- REDEMPLO launch momentum continues strong with prescriptions accelerating nearly threefold over the quarter and surpassing 400 total prescriptions since launch.
- Approximately 85% of prescriptions are from APOC3 class-naive patients, indicating growth via newly identified FCS patients.
- Prescription growth shows geographic breadth across the U.S., suggesting scalable patient identification and durable demand.
- Early patient persistence and satisfaction data are encouraging for sustained usage.
- Plans to expand REDEMPLO into the severe hypertriglyceridemia (SHTG) market with SHASTA-3 and SHASTA-4 Phase III data readout expected in Q3 2026.
- Anticipated clinical data readouts (ARO-DIMER-PA, ARO-MAPT) and additional obesity/NASH programs could drive pipeline growth and future revenue.
2 more points from Arrowhead Pharmaceuticals, Inc.'s call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
See what Arrowhead Pharmaceuticals, Inc. said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Arrowhead conducted its largest fundraising ever in the recent quarter, raising over $1 billion through public offerings of convertible senior notes and common stock, strengthening the balance sheet to support ongoing and future investments.
- Capital investment is focused on advancing clinical development programs, including Phase III studies for plozasiran in severe hypertriglyceridemia (SHTG) and early-stage programs like dimer and MAPT.
- Strategic investments also include expanding commercial infrastructure to support REDEMPLO and future potential launches (e.g., SHTG and HoFH treatments).
- The company entered an exclusive worldwide license agreement with Madrigal for ARO-PNPLA3 to advance this asset via partnership rather than internal capital allocation.
2 more points from Arrowhead Pharmaceuticals, Inc.'s call on capex
Pro opens every point from 15K+ earnings calls
Fundraising & Capital Structure
See what Arrowhead Pharmaceuticals, Inc. said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- More than 400 prescriptions for REDEMPLO have been written since its launch.
- Approximately 30 new prescriptions are being written each week currently.
- Over 10% of these prescriptions are from patients switching from a competitor's APOC3 inhibitor.
2 more points from Arrowhead Pharmaceuticals, Inc.'s call on order book
Pro opens every point from 15K+ earnings calls
Continue your research
Others in Biotechnology this season
- Madrigal Pharmaceuticals, Inc. (Q2 FY26)
Madrigal Pharmaceuticals, Inc. Q2 FY26 quarterly results analysis. The company expects steady patient additions and robust net sales growth through 2026, with Q
- Exelixis, Inc. (Q2 FY26)
Exelixis, Inc. Q2 FY26 quarterly results analysis. CABOMETYX revenue and demand continue strong growth; Q1 2026 U.S. Market Cap $12,932, P/E 16.5. AI-powered ea
- Ionis Pharmaceuticals, Inc. (Q2 FY26)
Ionis Pharmaceuticals, Inc. Q2 FY26 quarterly results analysis. DAWNZERA sales expected at $110M-$120M in 2026, driven by switches from existing prophylactics a
- BridgeBio Pharma, Inc. (Q2 FY26)
BridgeBio Pharma, Inc. Q2 FY26 quarterly results analysis. Attruby franchise shows durable growth with a 24% increase in net sales from Q4 and 392% YoY growth i
Arthneeti Pro · Annual
Arrowhead Pharmaceuticals, Inc. and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Arrowhead Pharmaceuticals, Inc. Q2 FY26 results?
- REDEMPLO launch momentum continues strong with prescriptions accelerating nearly threefold over the quarter and surpassing 400 total prescriptions since launch. - No specific future guidance on earnings, operating earnings, profits, or EPS was provided during the call.
What is Arrowhead Pharmaceuticals, Inc. share price analysis?
Arrowhead Pharmaceuticals, Inc. currently shows a moderate growth signal based on ranking data. The stock trades at a P/E of -18.1 with a market cap of $11,135. Investors should review the full earnings analysis for detailed insights.
Is Arrowhead Pharmaceuticals, Inc. planning capital expenditure?
- Arrowhead conducted its largest fundraising ever in the recent quarter, raising over $1 billion through public offerings of convertible senior notes and common stock, strengthening the balance sheet to support ongoing and future investments.
Keep Arrowhead Pharmaceuticals, Inc. on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.